Kemwell Biopharma Pvt. Ltd.

4 articles with Kemwell Biopharma Pvt. Ltd.

• Ocugen Engages Kemwell Biopharma for cGMP Manufacture of OCU200Paves the way towards getting OCU200 in the clinic by 1H 2022 as planned

  10/6/2020

  Ocugen, Inc. , (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced it has entered into an agreement with Kemwell Biopharma Pvt. Ltd. (Kemwell) to manufacture OCU200 , Ocugen’s novel biologic product candidate in preclinical development for treating severely sight-threatening diseases like Diabetic Macular Edema (DME), Diabetic

• Kemwell Biopharma Selected to Manufacture the Monoclonal Antibody Drug Substance For a US Phase 3 Clinical Trial

  6/5/2018

  Kemwell Biopharma, a biologics contract development and manufacturing service provider, announced today that it has signed a contract to manufacture and supply drug substance using its state-of-the-art mammalian cell culture plant in India for Phase 3 clinical trials that will be conducted in the US by its customer for a BLA filing.

• Kemwell Biopharma Supplies Biologics Drug Substance For Phase l Clinical Trials For U.S. IND Filing

  5/17/2017

• Recipharm AB Completes Acquisition Of Kemwell Pharma And Cirrus Pharmaceuticals, Inc. And Resolve On Share Issues

  5/23/2016